J&J: long-term antipsychotic drug approved in Europe

(CercleFinance.com) - Janssen, Johnson & Johnson's biopharmaceutical subsidiary, announced on Tuesday that the European Commission has approved the marketing of Byannli, its long-term treatment for schizophrenia.


The drug - which can be taken twice a year - becomes the longest-acting antipsychotic on the market in Europe.

Janssen says the green light from Brussels is based on clinical data showing that 95.2% of patients treated with this dosage did not experience a relapse of their illness after 12 months of observation.


Copyright (c) 2021 CercleFinance.com. All rights reserved.